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Abstract Surface plasmon resonance is a powerful tool to
examine the kinetics of cell surface receptor-ligand interactions
and requires only small amounts of protein. For these studies, one
component is required in highly purified form to be coupled to the
biosensor surface. The second component does not need to be
purified. The human high affinity receptor for immunoglobulin
G, FcQRI, presents a problem as the receptor itself cannot readily
be produced in large amounts for purification and, as there are
eight potential ligands for the receptor (human IgG1^4 and
mouse IgG1, 2a, 2b and 3), it is difficult to immobilise the ligand.
Using a previously established method for generating GPI-
anchored proteins, we have produced and captured a soluble
version of FcQRI and shown that it retains its affinity for human
IgG1 and specificity for the different IgG subclasses. In addition,
we also produced and captured a GPI-anchored version of the
cell adhesion molecule CD2. This system circumvents the need
for extensive receptor purification and is very rapid as solubilised
receptors can be transferred from the cell surface to the sensor
chip in 2 h. This system may be generally applicable for biosensor
studies to other type I membrane proteins, and/or naturally
occurring GPI-anchored proteins, especially where the interac-
tion between a ligand and a panel of variant receptors is to be
studied.
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1. Introduction
The study of protein-protein interactions by surface plas-
mon resonance (SPR) has become widespread in recent years.
However, the study of receptor-ligand interactions by SPR
requires the production of a soluble form of the receptor.
Several groups have used a variety of di¡erent methods of
producing soluble receptors to study the interaction with their
ligand [1^4]. In these cases, careful modi¢cation of the pro-
teins was required followed by over-production and puri¢ca-
tion, prior to analysis by SPR.
We are interested in the interaction between IgG and its
high a⁄nity receptor, FcQRI. FcQRI is a type I membrane
protein expressed on macrophages, monocytes and dendritic
cells where it plays a pivotal role linking the cellular and
humoral arms of the immune system (for reviews see [5^7]).
Binding of IgG to FcQRI triggers a variety of biological re-
sponses [8^10]. The extracellular ligand binding domain of
FcQRI comprises three V-like IgSF domains, EC1, EC2 and
EC3 [11,12]. We have shown that both EC2 and EC3 are
required for high a⁄nity binding of IgG, and that amino
acids in the second EC domain are important for ligand con-
tact (Harrison and Allen, submitted). To further characterise
this interaction between FcQRI and IgG, we have decided to
study the interactions between FcQRI and IgG using SPR.
Our initial attempts to produce a soluble version of the re-
ceptor where the second amino acid of the predicted trans-
membrane domain [11] was replaced by a stop codon were
unsuccessful : when the cDNA for the truncated receptor was
expressed in COS cells no soluble FcQRI could be harvested as
the protein appeared to be targeted for degradation. Similar
results have been found independently in another laboratory
(P.M. Hogarth, personal communication). Therefore, we have
assessed the feasibility of using glycosyl phosphatidyl inositol
(GPI)-anchored proteins to produce a soluble protein suitable
for plasmon resonance studies.
GPI proteins are attached to the extracellular surface of the
cell membrane via a phosphatidyl inositol linkage. This glyc-
osidic bond can be enzymatically hydrolysed using phospha-
tidyl inositol phospholipase C (PI-PLC), liberating the protein
from the cell surface, to produce a soluble protein [13,14].
FcQRI was expressed as a GPI-anchored protein, using a cas-
sette method for generating GPI-anchored versions of type I
membrane proteins [15]. The soluble form of FcQRI produced
in this way could be captured by speci¢c monoclonal anti-
bodies. The captured FcQRI could bind IgG subclasses with
the same speci¢city as FcQRI expressed on the surface of
monocytes/macrophages. This methodology was also success-
fully applied to CD2, a T-cell-speci¢c adhesion molecule. It is
envisaged that this technique could be used for the study of a
variety of type I membrane proteins with their ligands.
2. Materials and methods
2.1. Transient expression
COS-7 cells (obtained from B. Seed) were maintained in Dulbecco’s
modi¢ed Eagle’s medium (Gibco BRL) supplemented with 10% calf
serum, 2 mM glutamine, 100 IU/ml penicillin and 100 mg/ml strepto-
mycin. COS cells were plated at a density of approximately 4U107
cells per 100 mm plate 1 day before transfection. The SV40-based
expression vector CDM [16] was used for the transient expression
for all clones in COS cells using the DEAE-dextran method [11].
cDNAs for FcQRI-GPI (and FcQRI mutants) and CD2-GPI were
available in CDM [9]. Soluble protein was harvested at 2 or 3 days
post transfection, when surface expression is maximal.
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2.2. Production of soluble form of GPI-anchored proteins
COS cells transfected with FcQRI-GPI, CD2-GPI or vector only
were removed from plates using 1 mM EDTA/PBS, washed once
with HBS (10 mM HEPES pH 7.4, 150 mM NaCl, 3.4 mM
EDTA), resuspended in 1 ml of HBS with 5 units of PI-PLC (Oxford
Glycosystems), and incubated at 37‡C with gentle rotation, for 90
min. Cells were then spun out at 1500Ug and the protein stored at
370‡C or used immediately.
2.3. Antibodies
Human and mouse IgG subclasses, and goat anti-mouse (GKM)
IgG1 (Fc-speci¢c) were from Sigma. Anti-FcQRI monoclonal antibod-
ies 22 and 32, both mIgG1 subclass, and monoclonal 197, a mouse
IgG2a, were a gift from Medarex, anti-CD2 mAb MT910 (mIgG1
subclass) was from Dako Ltd, and anti-CD2 mAb XIX.8 (mIgG2a
subclass) was from Sera-Lab Ltd.
2.4. Immobilisation of GKM IgG1 on biosensor CM-5 chip
5 Wg of GKM IgG1 in a ¢nal volume of 100 Wl of 10 mM sodium
acetate bu¡er (pH 4.8) was injected over the surface of a CM-5 sensor
chip (Pharmacia Biosensor), and chemically immobilised using NHS
and EDC in accordance with the manufacturers’ instructions. All
injections were 10 Wl unless otherwise stated. The £ow rate was set
at 10 Wl/min for all experiments unless otherwise stated. The sensor
chip was regenerated with 100 mM glycine bu¡er, pH 2.5.
2.5. Addition of mAbs to GKM IgG1 to the CM-5 sensor chip to
capture GPI proteins
Following direct coupling of GKM IgG1 to the CM-5 sensor chip,
mAbs were used to capture the GPI proteins. To capture FcQRI-GPI,
both mAbs 22 (710 ng) and 32 (366 ng) were injected (10 Wl injection)
over the CM-5/GKM IgG1 surface. To capture CD2-GPI, mAb
MT910 (155 ng) was injected (10 Wl injection) over the CM-5/GKM
IgG1 surface. Following binding of GPI-anchored proteins, a second
mAb was used to con¢rm the identity of the bound protein. To
identify bound FcQRI-GPI, 10 Wl mAb 197 (200 ng) was injected.
To identify bound CD2-GPI, 10 Wl mAb XIX.8 (100 ng) was injected.
2.6. Binding of GPI proteins
10 Wl of the FcQRI-GPI protein was injected over the CM-5/GKM
IgG1 surface, that had already captured mAbs 22 and 32. The cap-
tured FcQRI-GPI protein was used for subsequent experiments to
determine the a⁄nity for human IgG1 and the speci¢city for various
IgG subclasses. For the a⁄nity measurements, the £ow rate was
reduced to 5 Wl/min although some of the measurements were also
repeated at a £ow rate of 20 Wl/min (data not shown) to ensure that
the kinetic parameters were una¡ected by £ow rate. The kinetics of
association and dissociation of human IgG for FcQRI was meas-
ured over four di¡erent concentrations of the ligand (Table 1). The
kinetics of the interaction were analysed using BIA evaluation 2.1
software and calculated for the di¡erent concentrations of ligand.
All calculations were performed after subtraction from a reference
£ow cell (blank) where the primary antibody (GKM IgG1) was not
coupled to the chip but was otherwise treated in an identical way to
the experimental cell. This blank was used to account for bulk
refractive index changes and non-speci¢c binding. For the CD2-GPI
studies a 10 Wl injection was also used for the capture of CD2-GPI
protein.
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Fig. 1. Schematic representation of the ELISA-like system to capture soluble FcQRI-GPI. GKM IgG1 (Fc-speci¢c) was covalently immobilised
to the CM-5 sensor chip surface. A: The immobilised GKM IgG1 (Fc-speci¢c) then captures anti-FcQRI mAbs, 22 and 32, which in turn cap-
ture FcQRI-GPI. The captured FcQRI-GPI can be recognised by other anti-FcQRI mAbs or bind IgG. B: The immobilised GKM IgG1 (Fc-spe-
ci¢c) then captures the anti-CD2 mAb, MT910, which in turn captures CD2-GPI. The captured CD2-GPI can be recognised by a second anti-
CD2 mAb.
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3. Results
3.1. Production and capture of soluble FcQRI-GPI protein
We have previously described a method for the production
of GPI-anchored version of type I transmembrane proteins,
using as examples a low a⁄nity adhesion molecule CD2 and a
high a⁄nity receptor molecule, FcQRI [15]. To generate solu-
ble forms of these molecules, COS cells transiently expressing
either CD2-GPI or FcQRI-GPI were treated with PI-PLC. The
supernatant from the treated cells was then injected directly,
without further puri¢cation, across the appropriately prepared
CM-5 sensor chip surface on a BIAcore 2000 (BIACORE,
Stevenage, UK).
To detect the presence of the soluble GPI proteins in the
supernatant of PI-PLC-treated cells, we devised an ‘ELISA-
like’ sandwich assay system on the sensor surface (see Fig.
1A). GKM IgG1 (Fc-speci¢c) was chemically immobilised
on the sensor surface. Once covalently coupled, this antibody
was used to capture monoclonal antibodies of the mIgG1
subclass to identify speci¢c GPI proteins. This approach has
two advantages compared to coupling the mAbs directly to
the sensor surface. First, because the GKM IgG1 is speci¢c for
the Fc region of the mAbs, the Fab region of these antibodies
will be correctly orientated for binding of their target protein.
Second, the non-covalently captured mAbs can be stripped
from the covalently coupled GKM IgG1 at the end of an
experiment, and the regenerated surface used to capture other
mAbs to detect other target proteins. Thus, only one £ow cell
of a sensor chip is required to detect a variety of di¡erent
proteins.
To detect soluble FcQRI-GPI, two anti-FcQRI mAbs (22
and 32) which use non-overlapping epitopes and do not a¡ect
IgG binding [17] were captured onto the GKM IgG1 sensor
chip (Fig. 1A). Both anti-FcQRI mAbs (22 and 32) were used
together based upon the observation that FcQRI is immuno-
precipitated much more e⁄ciently with both than either alone.
As shown in Fig. 2, the injection of 22/32 results in 693 RU of
binding. Injection of PI-PLC-treated supernatant from FcQRI-
GPI expressing COS cells resulted in a further 66 RU of bind-
ing. In contrast, injection of supernatant from PI-PLC-treated
mock-transfected or CD2-GPI-transfected cells yielded none
(data not shown). Thus, PI-PLC-solubilised FcQRI-GPI can
be readily captured by this system. The identity of the cap-
tured protein as FcQRI could be con¢rmed when the mAb 197
(mIgG2a subclass) was injected (Fig. 2). Similar results were
used when the mAb 10.1 [18] was used (data not shown).
However, since this mAb displaces IgG binding to FcQRI,
we used the detection system employing both 22 and 32 in
all subsequent experiments.
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Fig. 2. Sensorgram showing the binding of various proteins to the GKM IgG1 (Fc-speci¢c) sensor chip surface. Anti-FcQRI(22/32) mIgG1:
injection of anti-FcQRI mAbs 22 (mIgG1) and 32 (mIgG1); FcQRI-GPI: injection of FcQRI-GPI.
Table 1
Kinetic analysis of hIgG1 binding FcQRI-GPI
Flow rate (Wl/min) hIgG1 conc (WM) kass (104 M31 s31) kdiss (1033 s31) KD (1037 M)
5 6.67 1.97 2.00 1.01
5 4 1.24 2.18 1.75
5 2.67 2.1 2.22 1.05
5 1.33 1.97 2.23 1.13
Mean kass : 1.82U104 þ 0.39U104 M31 s31 ; mean kdiss : 2.16U1033 þ 0.11U1033 s31 ; mean KD : 1.24U1037 þ 0.35U1037 M.
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3.2. Captured FcQRI retains its a⁄nity for human IgG1 and its
speci¢city for human and mouse immunoglobulin subclasses
Having shown that FcQRI could be captured using mAbs 22
and 32, and bind polyclonal human IgG, we wished to see if it
retained its kinetic properties for the binding of human IgG1,
and speci¢city for di¡erent human and mouse IgG subclasses.
For the measurements of the kinetics of the interaction of
FcQRI with ligand, the sensorgram was subjected to the BIA
evaluation 2.1 software package. The observed rate of associ-
ation matched that predicted for a simple A+B3AB associ-
ation model within a M2 of 0.08 (Fig. 3). Direct measurements
of the kass and kdiss were consistent over a range of concen-
trations of the ligand (human IgG1) (Table 1) and £ow rates.
The average kass was 1.82U104 þ 0.39U104 M31 s31 and kdiss
2.16U1033 þ 0.11U1033 s31. The overall a⁄nity was calcu-
lated from these kinetics and gave an average KD of
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Fig. 4. Sensorgram showing the binding of human and mouse IgG subclasses to captured FcQRI-GPI. hIgG1, hIgG4, mIgG2a and mIgG3
bind, but hIgG2 and mIgG2b do not bind. The trace for human IgG2 displays mass transport e¡ects.
Fig. 3. BIA evaluation 2.1 curve ¢t for the association of FcQRI for human IgG1. This curve shows the area of the sensorgram used to calcu-
late the kass. The dashed line shows the ideal ¢t for the simple association model A+B3AB. The rate constants were obtained using linear re-
gression analysis.
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0.123U1038 þ 0.035U1038 M, a result comparable to that
observed for FcQRI when expressed on the surface of macro-
phages and macrophage-derived cell lines [19^21]. It is slightly
higher than the value for FcQRI expressed on the surface of
COS cells [11].
FcQRI endogenously expressed on the surface of macro-
phages or monocytes, or heterogeneously expressed on the
surface of COS cells will bind human IgG1, IgG3 and IgG4
and mouse IgG2a but not human IgG2 or mouse IgG1 or
IgG2b. As shown in Fig. 4, captured FcQRI-GPI speci¢cally
bound human IgG1, hIgG3 and hIgG4 and also mouse IgG2a
(Table 2). The captured receptor did not bind human IgG2 or
mIgG2b. In the absence of captured FcQRI-GPI no binding of
any IgG subclasses is observed (data not shown). mIgG1
could not be tested as it is bound directly by the immobilised
GKM IgG1-speci¢c antibody. Attempts to block all the
mIgG1 binding sites with an excess of mIgG1 were not suc-
cessful, so we cannot at present con¢rm that mIgG1 is not
recognised.
3.3. Production and capture of soluble CD2-GPI protein for
SPR analysis
To identify CD2-GPI, the mAb MT910 (mouse IgG1 sub-
class) was used as shown in Fig. 1B. As shown in Fig. 5,
injection of PI-PLC-treated supernatant from COS cells ex-
pressing CD2-GPI resulted in 354 RU binding, whereas in-
jection of supernatant from PI-PLC-treated mock-transfected
or FcQRI-GPI-transfected cells yielded none.
To con¢rm that the captured moiety was CD2, a di¡erent
anti-CD2 mAb, XIX.8 (which is of the mIgG2a subclass and
is not be recognised by the immobilised GKM IgG1-speci¢c
antibody) was injected. This resulted in 155 RU of binding. In
contrast, injection of mAb XIX.8 in the absence of a prior
injection of CD2-GPI gave no increase in RU. This shows
that the mAb XIX.8 binds a di¡erent non-overlapping epitope
from MT910.
4. Discussion
We have shown that soluble protein produced by PI-PLC
treatment of GPI-anchored receptors can be detected by an
‘ELISA-like’ capture system on a BIAcore sensor surface and
that the captured proteins can be used to study receptor-li-
gand interactions. By immobilising a GKM IgG1 Fc-speci¢c
antibody, and using that to capture monoclonal antibodies of
the mouse IgG1 subclass, we were able to make a reusable
detection system able to recognise di¡erent GPI-anchored
proteins. The ¢rst protein captured was solubilised FcQRI-
GPI. The proteins identity was veri¢ed by the binding of
another FcQRI-speci¢c mAb, 197. Moreover, the captured re-
ceptor retained the ability to bind human IgG1 with similar
a⁄nity to that measured for the receptor expressed on the cell
surface. More importantly, its speci¢city for six di¡erent IgG
FEBS 19795 5-2-98
Fig. 5. Sensorgram showing the binding of various proteins to the GKM IgG1 (Fc-speci¢c) sensor chip surface. KCD2 (mIgG1) MT910: injec-
tion of anti-CD2 mAb MT910 (mIgG1); CD2-GPI: injection of CD2-GPI; aCD2mIgG2a (x1x.8): injection of mAb XIX.8 (mIgG2a).
Table 2








At time point 400 s.
The relative amount of each of the IgG subtypes bound to FcQRI was
calculated by measuring the resonance units after the injection (400 s)
of each of the various IgG subtypes and subtracting the pre-injection
value at 95 s; see Fig. 4.
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subclasses. The second protein captured was solubilised CD2-
GPI. Its identity was veri¢ed by the binding of another CD2-
speci¢c mAb, XIX.8.
The use of GPI-anchored proteins, coupled with the ‘ELI-
SA-like’ system described here, o¡ers several advantages when
compared to other systems used to generate soluble proteins
for analysis by SPR. The major advantage is that the protein
does not require puri¢cation prior to use. This is due to the
fact that the GPI protein is, in e¡ect, a⁄nity puri¢ed when
injected over the sensor surface by the appropriately captured
mAbs. A second advantage is that the protein can be easily
pre-concentrated whilst still attached to the cell surface. Usu-
ally a total of about 106 cells are harvested from four 100 mm
dishes and the cells concentrated into 0.5 ml before being
subjected to PI-PLC treatment. Another major advantage is
speed; the protein can be transferred from the cell surface to
the sensor surface in approximately 2 h. Since the sensor chip
surface can be rapidly regenerated, this means that many dif-
ferent receptors can be assayed using the same chip. This is
especially useful if the interaction between a ligand and a
panel of variant receptors is to be assayed. Finally, the con-
version of type I membrane receptors into GPI-anchored pro-
teins requires little genetic manipulation [14,15].
The vector described here for expressing GPI proteins can
be e⁄ciently transfected into COS cells and results in very
high levels of cell surface expression; the transfection e⁄-
ciency of FcQRI-GPI is in excess of 30% in COS cells [15]
and 106^107 copies of FcQRI are expressed per COS cell
[11]. Thus, although endogenous GPI proteins will be released
following PI-PLC digestion, along with the protein of interest
(e.g. FcQRI-GPI), the extracellular region of the heterolo-
gously expressed GPI-anchored protein is the predominant
protein.
We intend to explore the use of this system for obtaining
kinetic data for the interactions between FcQRI and IgG. We
also wish to extend the scope of this system for more detailed
epitope mapping applications and explore the possibility of
studying the interactions between IgG and a panel of FcQRI
variants.
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